Physician profile
Patrick N Andre
NPI 1386647303
$1,407.79
in general payments reported to CMS, 2019-2025
20 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $271 · 2021: $11.40 · 2022: $17.04 · 2023: $97.41 · 2024: $282 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $252.60 | 2021-2025 | Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $216.80 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $210.88 | 2019-2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $147.44 | 2023-2025 | Trelegy Ellipta |
| Neuronetics, INC. | $115.74 | 2020 | |
| Lilly USA, LLC | $84.19 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $71.18 | 2020-2025 | Evenity, Otezla, Repatha |
| Astellas Pharma US INC | $61.41 | 2019-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.35 | 2020-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $38.08 | 2020 | |
| Sanofi-Aventis U.S. LLC | $37.02 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.71 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $17.27 | 2023 | |
| Eisai INC. | $15.96 | 2020 | |
| Genentech USA, INC. | $14.47 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.90 | 2024 | |
| Allergan, INC. | $13.65 | 2019 | |
| Sanofi Pasteur INC. | $12.39 | 2019 | |
| Avanir Pharmaceuticals, INC. | $10.96 | 2019 | |
| Phathom Pharmaceuticals, INC. | $7.79 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Andre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.